V501
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cervical Cancer
Conditions
Cervical Cancer, Cervical Intraepithelial Neoplasia, Adenocarcinoma in Situ
Trial Timeline
Nov 25, 2011 → Aug 27, 2016
NCT ID
NCT01544478About V501
V501 is a approved stage product being developed by Merck for Cervical Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01544478. Target conditions include Cervical Cancer, Cervical Intraepithelial Neoplasia, Adenocarcinoma in Situ.
What happened to similar drugs?
7 of 20 similar drugs in Cervical Cancer were approved
Approved (7) Terminated (0) Active (13)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03493542 | Phase 3 | Completed |
| NCT02576054 | Phase 3 | Completed |
| NCT01544478 | Approved | Completed |
Competing Products
20 competing products in Cervical Cancer